EUVIMEDEUVIMED entdecken
Übersichtsarbeit

NanoTAC in targeted protein degradation: Intelligent delivery platforms and synergistic therapeutic paradigms

Jieying Qian, Hongtao Duan, Qingqi Zheng, Yuzhao Yang, Xiaowan Huang, Bingyang Shi, Yunjiao Zhang

Advanced Drug Delivery Reviews · 2026

DOI: 10.1016/j.addr.2026.115821 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Advanced Drug Delivery Reviews, 2026. Verfasst von Jieying Qian und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, South China University of Technology, Guangzhou 510006, PR China. Hauptthemen laut MEDLINE: Nanoparticles, Drug Delivery Systems, Proteolysis, Proteins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 119 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China Stem Cell and Translational Research, Fundamental Research Funds for the Central Universities.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeted protein degradation (TPD) has reshaped therapeutic strategy by catalytically eliminating pathogenic proteins through engagement with endogenous proteolytic systems. In contrast to conventional inhibitors that transiently block enzymatic activity, TPD achieves durable target silencing by physically removing the protein entirely, thereby overcoming resistance mechanisms and extending therapeutic durability. This approach enables the pharmacological modulation of previously "undruggable" entities, such as transcription factors and scaffolding proteins, that lack canonical binding pockets. However, clinical translation of existing TPD platforms, including PROTACs and molecular glues, remains limited by poor bioavailability, off-target toxicity, and suboptimal tissue selectivity. Nanoparticle-assisted targeted protein degraders (NanoTACs) offer a compelling solution by coupling the catalytic efficiency of TPD with the spatial precision and tunability of nanotechnology. Through rational nanocarrier engineering, NanoTACs overcome key limitations of small-molecule degraders, including poor solubility, rapid systemic clearance, and inadequate targetability, while enabling direct and selective degradation of pathogenic proteins with minimal structural modification. This integration affords programmable control of biodistribution, cellular uptake, and release kinetics, as well as microenvironment-responsive degradation that is difficult to achieve with traditional modalities. Beyond functioning as delivery vehicles, NanoTACs actively recruit degradation machinery, modulate intracellular proteostasis, and permit synergistic co-delivery of therapeutic payloads. Emerging data demonstrate their capacity to degrade oncogenic drivers, suppress inflammatory signaling, and eliminate pathological protein aggregates across diverse disease models. This Review delineates the conceptual foundations, design principles, and translational prospects of NanoTACs, positioning them as a next-generation platform at the intersection of nanomedicine, chemical biology, and precision oncology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NanoparticlesDrug Delivery SystemsProteolysisProteinsNanoparticle Drug Delivery SystemHumansAnimalsProteolysis Targeting Chimera

Stichwörter der Autor:innen

Disease therapyDrug deliveryNanoTACTargeted protein degradation (TPD)

Substanzen

Proteolysis Targeting ChimeraProteinsNanoparticle Drug Delivery System

Autor:innen und Institutionen

  • School of Medicine, South China University of Technology, Guangzhou 510006, PR China.
  • Department of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119074, Singapore.
  • Henan-Macquarie University Joint Centre for Biomedical Innovations, School of Life Sciences, Henan University, Kaifeng, Henan, China.
  • School of Medicine, South China University of Technology, Guangzhou 510006, PR China; National Engineering Research Center for Tissue Restoration and Reconstruction and Key Laboratory of Biomedical Engineering of Guangd…

Förderung

  • National Natural Science Foundation of China
  • National Key Research and Development Program of China Stem Cell and Translational Research
  • Fundamental Research Funds for the Central Universities
  • Medical Science and Technology Foundation of Guangdong Province
  • Guangdong Provincial Natural Science Foundation
  • National Key Research and Development Program of China

Zitieren

APA

Qian, J., Duan, H., Zheng, Q., Yang, Y., Huang, X., Shi, B., & Zhang, Y. (2026). NanoTAC in targeted protein degradation: Intelligent delivery platforms and synergistic therapeutic paradigms. Advanced Drug Delivery Reviews. https://doi.org/10.1016/j.addr.2026.115821

Vancouver

Qian J, Duan H, Zheng Q, Yang Y, Huang X, Shi B, et al. NanoTAC in targeted protein degradation: Intelligent delivery platforms and synergistic therapeutic paradigms. Advanced Drug Delivery Reviews. 2026. doi:10.1016/j.addr.2026.115821

BibTeX
@article{Qian2026,
  author = {Qian, Jieying and Duan, Hongtao and Zheng, Qingqi and Yang, Yuzhao and Huang, Xiaowan and Shi, Bingyang and Zhang, Yunjiao},
  title = {NanoTAC in targeted protein degradation: Intelligent delivery platforms and synergistic therapeutic paradigms},
  journal = {Advanced Drug Delivery Reviews},
  year = {2026},
  doi = {10.1016/j.addr.2026.115821}
}
Kostenlos starten →